glp 1 lean mass loss GLP-1 agonists and changes in body and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis GLP-1 based drugs: Could Elon

Approved GLP-1 drugs have known side effects, especially gastrointestinal symptoms, and carry label warnings that require medical oversight [910]

Addressing recent docking challenges: a hybrid strategy to integrate template-based and free protein-protein docking

DPP-4 inhibitors for treating diabetes Just as exenatide was making its way to approval for type 2 diabetes, another type of drug had appeared on the scene for the disease

#Testosterone Interesting finding

Step-by-Step: Building a Supportive Routine Creating a routine doesnt have to be complicated

Abstract Aims/hypothesis We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus decreases the risk of new-onset adverse cardiovascular events (CVEs) and mortality rate compared with other glucose-lowering drugs in a real setting at a population level